Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Medicover, Webcast, Investor Update, 2026

By Inderes2/11/2026, 12:00 PM
Medicover

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:08 - 01:45

What happens when you drop hope into the world? 30 years ago, we made our first ripple. A single vision in Central Europe. Healthcare should be exceptional, not exclusive. One clinic became a network. One dream became a movement across borders and cultures. Each ripple carried the same promise. Healthcare without compromise. Patients are truly seen. Families have easy access to quality care. Communities discover they are at the center of medical excellence. The ripples grew stronger. Each new country, each new facility, each new partnership amplified our impact. We weren't just building hospitals, we were building hope. Now our ripples have become waves, from the heart surgeon in Mumbai to the genetic counselor in Berlin, from the fitness instructor in Warsaw to the laboratory technician in Bucharest. We are connected by care. Innovation flows through everything we do. Robotic surgery systems guide our surgeons with millimeter precision. Virtual reality headsets calm anxious children during procedures, turning fear into fascination. Genetics advancements are changing lives. We're creating an ocean of possibility. Each person we help heal creates waves of wellness in their families, their communities, their futures. 30 years of care and many more ahead. We are shaping a healthier tomorrow.

Matthias Waldstein
01:54 - 03:29

Good. With this brief video. Warm welcome to Medicover investor update. My name is Matthias Waldstein. I work as an equity analyst at SIB. I have the privilege to lead this session as a moderator today. I'm responsible for covering Medicover at OECD. Whether you're joining us here in Stockholm. Many of you are, or online. We're delighted to have you all here. I will start by giving you a brief introduction to the agenda. We will have two speakers today. John Stubbington, CEO of Medicover, and Anand Patel, CFO. So, John will start with a business overview, strategy introduction. And then we will have the financial highlights by Anand. So after each presentation, we will open the floor for questions. Online attendees may raise their hands during designated Q&A segments of this presentation. For in-person attendees, please wait for a microphone. Please submit your questions via the chat function at any time and I will address them. Lastly, as an analyst in the past, I know you don't need to take photos during the session because it will be readily available online. So I think with those introductions, I'm pleased now to hand over to CEO John Stubbington.

Unknown 5
03:44 - 53:30

Good afternoon everybody. It's my pleasure and duty today to talk to you through a little bit of our history and a lot about our future. Medicover is a great company. When we listed a number of years back, it was an exciting time for us. It was a very unknown time for us. But as you can see, over that period of time we've grown quite considerably. This is an incredible growth story that has occurred over that period of time. And we're 33.8 times bigger than we were at the time of listing. Most of that growth has come from organic growth, which is really, really good. We've managed to develop our markets and move our business forward. And of course, we've complemented it with the odd acquisition along the way, which has been very encouraging and added a lot to our portfolio. If we look at the targets that we set out three years ago, again, when we set those targets out, there were a lot of people saying to us, could we hit them? They're big numbers. There's a long way to go to be able to deliver them. We had COVID at the time that was distorting a lot of the numbers, so we knew that that would eventually subside and reduce some of our profitability and revenues over time. But I'm delighted to be able to say to everybody that we've got tick, tick, tick, tick, tick on all the indicators that we set out. But of course this is history. So this is now all gone and we need to move on to more exciting things. If we look at the business, just to give some context so that people can understand who we are, what we do, many people in the room know it and know it very well. Some people might, might not. So we will give some context. We've got two operating divisions. We've got Healthcare Services, which is 69% of the business. We have Diagnostic Services, which is 31% of the business. We've got some really strong assets in countries that give us the footprint to be able to develop our services, 187 clinics, 176 gyms, 41 hospitals, 6000 beds. An incredible number of beds that we have to serve our customers. 14.4 million visits is not a small number, 1.5 million members, and a really good payer mix when it comes to healthcare services on the right hand side. Again, really good footprint, 135 labs, lots of blood drawing points, some clinics to support all of that. And 152 million lab tests, which is quite a number, and a really good payer mix. Also in diagnostic services, if you look on the left-hand side, healthcare services is very synergistic with diagnostic services. Every time we put on some healthcare assets, we have to do blood testing, we have to do lab testing. So it fuels the right hand side. And every single time the right hand side gets creative and starts to put in place new tests, new capabilities. It fuels the left hand side, so it's highly synergistic. Although we're in many, many countries, 90% of our business is in four main countries: India, Romania, Germany, and Poland. Poland by far the biggest. Today, I'll talk you through all of those countries in terms of some of the developments that we're doing. So you've got some context and backdrop. Each country has a different business model. So it's not one business model that we're applying across each country. It's a different business model. And we're really in some exciting geographies. We're in countries where historically there's been a lack of investment in the infrastructure. There's been an increase, usually among the middle classes and people who can afford healthcare or private healthcare; they want a choice, and we provide it. And then if you look at the key indicators in terms of GDP growth, healthcare spend as a percentage of GDP, overall healthcare market growth, and private healthcare market growth. Each country has big numbers. GDP 3.2% to 6.8%. You're looking at healthcare. Spend all the way up to 12.3% there in terms of Germany and all the way down at 3.3%. Both are positive. So if 3.3 is low, that means there's an opportunity for healthcare to be delivered. If there's a lot of healthcare being delivered, then there's an opportunity for us to be part of that delivery system. So no matter how some of these indicators go, we're really well placed to be able to take advantage of it. And of course, we're in healthcare. These healthcare markets are big. And more importantly, the private sector within those healthcare markets is growing. So if you look at number four, you've got private healthcare market growth of 7.4%, 4.29%, and 13%. And later on, what you'll see is that we actually outgrow those particular market dynamics. So we're in a really positive position. And we've also got long-term relationships with our customers. Our customers tend to come and join us. And then they settle with us. And the patterns of what they want and what they need are changing. So people want more convenience and greater access to healthcare. There's an appetite to consume healthcare. There's an appetite to get better. They want a digital experience. They don't just want it to be face to face. They want to be able to control things themselves and have access to different information, and be able to manage their journey themselves, and to be able to see what their results have been in their history. And they're also moving into a different side of things when it comes to prevention and longevity. All these trends are really, really positive for us. And when we look at those trends, people want technology, and we have a really strong technology stack. We've got a lot of different applications that we've built over the years, many of them being things that we've self-built. It's our code. We've put them in place, resulting in really high engagement from consumers in terms of using these digital tools. A 4.6-star out of five is a really positive thing. If you get a 4.7 or 4.8, people start to doubt that what you've got is really there. So, we're right in the zone of where we need to be. And these tools engage. They get customers using you and thinking about your brand. They act as sales platforms. They enable the delivery of your services remotely. And they give us a complete view of what a customer is doing, what a customer needs, what the trends that are changing. So our technology stack is a really important part of our journey. Sorry, I went backwards, not forwards. What are we about as an organization? What we're about is healthcare and we're about health impact. So we measure that as well. We have an independent organization called Upright that looks at the difference that we make to society and the impact that we have in our healthcare delivery. And for every €1 of healthcare spend, €2.74 comes back in terms of impact. So that's quite a positive sort of thing. That somebody puts €1 with us. The health impact that that has on them is €2.74. It's quite a good return. And in terms of overall impact of everything that we've done, they've assessed that, currently in 2024, it was €330 million, which is very, very positive. And out of everything that we do, 92% of what we do is aligned to some of the objectives that are set out by the United Nations in terms of health impact, again, very, very positive. And within our delivery system, we've got a really big capability that's being delivered each and every day. One medical visit is happening every second. That's quite an incredible sort of achievement. There are 11 lab tests happening every second as well. Again, quite an incredible achievement. This is not totally related. They're different customer bases. So you haven't got one person coming in and being tested 11 times. But that's a really, really big impact that we're having on society and for people. And of course, we're delivering that in a very positive way when it comes to the NPS and how our customers view us with an 83 NPS score. And we're doing this in a very ethical, responsible and sustainable way, which I believe is what people want in today's society. So a really positive position for Medicover. But we need to move forward. And as we move forward, we need to look at the targets that we set for the future, and we set those out yesterday. I'm not going to deal with these in detail. I'm going to leave that to Alan to talk about as he comes on to do his session. They're ambitious. They're typical Medicover targets, which are ambitious. They're quite aggressive. People question whether we can achieve them or not. We believe we can. That's why we've set them out. And we're really looking forward to the journey of being able to deliver them. Okay, so how will we deliver them? What does that look like? We've got a few positive drivers that sort of help us. We've got the market growth that we think will happen in our countries, and strong market conditions which we will talk you through. We've got a good existing network. We've got lots of assets on the ground where we deliver healthcare. And that's very positive for us. But we've also got the opportunity to grow more. And as a consequence of growing the network more, we'll improve our financials. We've got good opportunities for synergies within our business model. And we think we can increase our productivity, which will again, really help our financial position. And again, we will continue to develop technology because when it comes to healthcare, people want more and more technology to be able to have choices on their healthcare solutions. And all of our core markets will help contribute to this. As we said before, 90% of our business is in four key markets, and we will drive growth in each one of them; our biggest market is Poland, which has 52% of our market share. We've got very good revenue growth there. Again, we'll compare that a little bit later on versus market conditions. Most of this is delivered through healthcare services. We have a very strong business model. So when it comes to our Polish proposition, what do we do? First and foremost, we acquire members. So we tend to go to businesses. Those businesses tend to want cover for their employees. We provide that cover. And as a consequence of providing that cover, we have to have facilities available to them. Access their care. So we build those facilities. Other members of the public say, well, I like those facilities and I wouldn't mind using those as well. And that gives us a bigger footprint because we bring in people that are not only funded members by employers in the main, but they're individuals that are coming off the street that are saying, 'Can I have health care as well?' Which means we've got to build even more facilities, because it's only appropriate that we've got enough healthcare delivery for the employees, but also the excess capacity for the Fee-for-Service community. And then what happens is that both of those communities start to say, 'My employer covers me for so much, but I would like some extra services that the employer doesn't cover.' And we start to build even more facilities that are related to things that aren't covered by the employer plan. And as a consequence of that, even more people from members of the public decide that they would like to use those facilities as well. All of that kind of delivery system that then gets delivered each and every day to our customers drives the business. Drives synergy within the group. It means that more people go to clinics. It means more people go to hospitals. It means more people go for lab tests and diagnostics. And of course, as they go for lab tests and diagnostics, our diagnostics division benefits from that. They get a steady stream of revenues. That's going to come from the healthcare services team, driving the healthcare delivery. And also they start to get creative and say to themselves, well, actually, we can do more services. And then the hospitals say they can do more services, and then we go around again and offer these services back to existing customers, which gives us a really good revenue mix and a really strong base. When we look at the healthcare market in Poland, the healthcare market in Poland is really attractive for us. You can see the GDP is strong, one of the strongest in Europe. You can see the healthcare market at 6.3% is big and very attractive to us. The private healthcare market is even bigger. And of course, in Poland we not only do healthcare delivery, we do sports and wellness as well. And that market's growing even faster. The population is aging and as a consequence of aging, they will require more healthcare, which again drives utilization up for us and gives us an opportunity to grow. And then the key insights of the market show that it is very, very attractive. Private healthcare at 11 billion, Public Pay at 7.4 billion, a market growth of 3 billion in healthcare and 1.5 billion in sport and wellness. So really, really big markets, we've got a very good market share, and we're actually growing at a much faster rate than the overall market. So again, this represents a very positive position. And then if you look at our footprint, it gives us a really good opportunity to grow. If you look on the left hand side here, we've added a tremendous amount of capability over a relatively short period of time in 2022. We have put on nearly 100,000m² of extra space. That extra space needs to be filled. We've started to fill it. If you look at the graph in the middle, you can see that the gray bar starts to show that the space is increasing. And then the revenues per square meter are starting to move up and our utilization is starting to move up. As we increase utilization, we obviously get more revenues. As we increase utilization, we get operational leverage. All of this is fully invested. We've already put our CapEx spend into these facilities. We've got the extra capacity to fill up over the course of the next few years. We will fill this capacity up. Customers will come to us, and more importantly, customers will come back. Then, when we consider the opportunity to grow outside of our existing network, we look for space to expand into areas where we are not currently present. If you look on the left-hand side in the pie chart, you can see that the top three providers in the country have a decent market share. But if you look at the total market, we've hardly penetrated the total market in terms of opportunity for healthcare. We've got lots of capabilities in each of the voivodeships in Poland, which is what you can see in the middle. But we've got more than enough opportunity to be able to put extra facilities in place. As we put those extra facilities in place, we will grow. As we grow, we'll get the operational leverage that will help our margins, that will help our growth rates. It's a really positive position for us. We have a very holistic proposition in Poland. It's very wide in terms of the capabilities we have available. We have services from pre-birth all the way into hospitalization. And of course, we see a movement not only of people wanting more healthcare, but they also want more health and wellness. And we therefore have an opportunity to develop our product range. And if we look at our product range across 2017, 2023, and 2025, we've developed different products and services. And if you look at the grey bars, the grey bars do actually represent real growth, real growth that has happened within the country in relation to some of that product development that we have done. So we have a history of being able to develop new products, new services, new offerings to consumers and businesses that attract them to spend more with us, because we are a brand. It's a brand that is trusted in Poland. It's a brand that's known for high-quality services and is able to deliver. So, in the old days, we just did healthcare. We then moved on to do what we call healthy company and healthy life, where we're offering much more holistic services and a broader offering, which included our sport and wellness. In 2025, we've developed our Healthy Courage Programme. This is a program which crosses over between healthcare and sports and wellness. We put a number of people through the program. We looked at it from a scientific perspective, and basically, if you engaged in the program and completed it over the course of a 12-month period, for every year you invested in the program, it equated to an extra year of life. And we've been able to prove that. Now we're currently talking to employers about its results: a 13% reduction in cardiovascular events, and a 27% greater sense of efficiency in daily life. You live one year longer. 32% reduction in illness. This is a really big program. It's a really big breakthrough for us. And currently we're talking to quite a lot of customers in terms of that new development. And it's this kind of thing that we will develop over time. These things, in terms of our history, if you go back years and years ago, most of our relationships were business-to-business, and most of our revenues were funded. But if you look at our revenue mix today, we've tremendously changed. And fee-for-service has become a much more important part of the revenue mix that we have. And that means that we not only need members, but we need relationships to develop and to explore. And we've got a strong number of relationships in Poland, people that we can talk to each day about healthcare, about their healthcare needs. And if you look at that population, on average, that population spends a lot of money on healthcare in Poland, and this spending is increasing. So that gives us an even greater opportunity. When customers and users join us, because we deliver high quality, their average spend with us is much greater. So again, we've got another opportunity to grow. And we look to make sure that we develop loyalty with those relationships and loyalty with our customers. We have a brand new loyalty program that we've put in place. It's embryonic in terms of its capabilities, but it is in place and growing very fast. It's another lever that we can pull in terms of ensuring we've got strong, deep relationships for the future. And if they come into our loyalty program, that gives us the opportunity to showcase all of our proposition in today's society. Dealing with a consumer is very difficult. You have to get consent for this. You have to get consent for that. You have to deal with things by legal entities. It's a minefield to be able to navigate. But through our loyalty program, once people decide to engage with us, we've got a greater opportunity to offer them more and more products within our group. And when they do go into our loyalty program and they do buy things, the revenues that they generate are much higher. They tend to come back more frequently, they tend to buy at a higher price, and they tend to buy more things, which is all very positive for us. We will in the future also develop some of our existing outlets and our existing infrastructure. We have a lot of blood drawing points in Poland. Those blood drawing points today just do blood drawing. We intend to change that so that it becomes more health hubs, where we can showcase our full proposition. So that gives us 154 new outlets to be able to use as point of sale. And we will expand the number of outlets as well. And we very much see that the activities we have in our gyms will not only be about fitness, but also about wellness, which means we've got nearly 300m² of space and thousands of people coming each and every day into our gyms to be able to showcase our full proposition for healthcare, which will drive even more growth. So from a Polish perspective, we think it's a very attractive market. We think we've got ample space to expand our presence. There's lots of white space to go. We're constantly developing our proposition, and it's highly synergistic. So very, very positive. A good driver for the future. I'll move on to Germany. Germany is a really important part of our diagnostic delivery system. If you look at our history, our lab business developed over a long period with different assets joining us. But Germany became central to it. Germany really is a place where we've got a lot of advanced diagnostics, and we take that capability and move it into our core market. So over time we develop Poland, over time we develop Romania. And then over time, Romania became a central hub for distribution of some of those advanced diagnostics and some of our genetics. So Germany becomes key in terms of being able to not only deal with Germany, but also support the other markets that we operate in. And this becomes a big distribution network across the whole of Europe from a healthcare delivery perspective. Germany as a market is very stable. GDP 1.3, healthcare market 4.4. Lab Diagnostics 4.2. Healthcare spending in Germany is very, very high. There are a couple of points on the healthcare spend. One is it showcases a bit about how far India, Romania and Poland have got to go in terms of their healthcare spend. So it shows how attractive those markets are, but also at the same time shows what a solid and big market Germany is for us. 5.1 billion in terms of the diagnostic market. And while the CAGR is relatively, relatively low, it is incredibly, incredibly stable. We've got a little bit of noise going on here, which I think we're due to sort out. It's incredibly stable. And we've got a good, strong market, and a nice growth position within the German market per se. But our play in Germany is really three things. It isn't one thing in isolation. Number one, we have a very regionally based lab business that is very strong and has done very well and has navigated reform incredibly, incredibly well, which again, we'll talk about as we go through. We also have a very national position in terms of some of our other services. We have advanced diagnostics, advanced testing, and genetics, which spread across the whole country. And we have the opportunity, which we've started to explore and execute, to go international with some of that property, some of that proposition, which means that we have more than one opportunity in Germany to develop our position. If we look at our regional lab, 95% of its revenues come locally. Naturally, people send their lab tests for the routine stuff very locally. But when it comes to specialized testing and genetics, we tend to have a much more national proposition. And not only that, once you've had the national proposition, once people nationally are getting used to using you, they then start to send some of the routine stuff back to the regional lab. The regional labs are in the north and northeast. And they benefit from that national footprint. So we've got a strong lab business. We've got a strong advanced diagnostic business. We've got a strong genetic business that leads to high levels of synergy. And you can see here on the left-hand side that regional lab position, 30% market share, which is a good market share to have. And we've shown over the last 12 months how resilient our German lab business can be. German reform came in a year ago. It was at the time a big worry for people. There was a big amount of fear. How can we navigate this? What can we do? What impact will it have on us? But if you look at our business over a two-year period and you say to yourselves, what size were we in 2023, where are we now in 2025? What's lab reform done to us? We've still grown our customer base. Our customer base has gone up 10%. We've still grown our test volumes. Our test volumes have gone up 15%, and we're still growing our revenues. So I think that's a great testament to the strength and depth of our lab team, but also represents Medicover. Medicover over the years gets many different challenges. These challenges come from reform and government. We have to be agile. We have to show that agility, refocus our business, adapt, and be able to come through. We can't necessarily do that every single quarter. It takes a little longer. But if you look at us over a long period of time, we adapt to some of these challenges. So we're well placed in Germany to grow. We've managed the reform, and it has created the beginnings of a transformation for us, which we're currently implementing. We've got good opportunity to drive some specialist lab testing. We've got a broad portfolio where we can get more business and we can expand our customer base. So we're well placed. We've also got some good market conditions. So, if you look at the market conditions and trends in Germany, many people are now interested in new things. You know, the reform has driven more health awareness. More people are talking about nutrition. More people are talking about anti-aging. So, not the traditional healthcare market positions, but more moving towards lifestyle testing. And as that lifestyle testing demand develops, our advanced diagnostic portfolio is ideally suited to meet those needs. So, we have some really good, attractive positions in Germany to grow our business, whether there is further reform or whether we continue as business as usual. So, if we look at it from an estimated market potential by 2030, from a German perspective, our specialized testing is 1.9 billion, and from our genetics, it's 0.9 billion. And then, of course, we've got our opportunities to go into our own network, which means across Romania, etc. And also to go internationally. So we're well placed. So from a German perspective, we can expand the customer base, we can broaden the portfolio, and we can drive our specialist lab testing. In Romania, we have two very strong divisions. We've got diagnostic services, which is our lab position. It's a very balanced business. It's a business that serves doctors and it's a business that serves consumers. And when it serves consumers, it's the most trusted brand in the country from a lab delivery perspective, very creative and innovative in terms of its position. And in healthcare, we have a business that's transforming, originally a membership business very much in the mode of the business that we had in Poland that has moved forward to be more focused on hospitals. Hospital is quite an important part of the delivery system from a Romanian perspective, mainly because it allows you to access two main revenue streams. The Romanian government allows you to blend out-of-pocket payments with government funds. So as long as you have got governmental funds, your fee for service will naturally grow because people expect to pay extra on top of accessing the public fund. And we're ideally placed both from a diagnostic perspective and a healthcare perspective to be able to serve the needs of Romania. Alongside that, we've got some really key enablers. We're very digitally enabled from a lab perspective. We've got our Polish technology stack being developed and deployed into Romania from a healthcare services perspective, that will allow us to drive more convenience and give a greater value proposition for doctors. If you look at the market from a GDP perspective, it's 2.3; if you look at the healthcare market, it's 6.9. And if you look at the private market, it's even bigger. And then if you look at the gap in spending from an OECD perspective, it's massive, 2.6 times. And you see that on the ground. You see that on the ground in terms of the members of the public looking to access healthcare, looking to access private healthcare, a big market of 6 billion, and Medicover's share is a decent 5%. So we've got a decent footprint, and our Medicover share in lab diagnostics is 18%, and actually our growth rates are much greater than that share. Again, same situation as we talked about before in Poland. We have a big increase in our square meters that we've put in place: 17,000 extra square meters have been added. That means that we've got much more capacity. You can see in terms of our revenue per square meter, it's starting to grow. You can see in terms of our capacity, there's a big gap in terms of space that we can grow into. All of that space has been fully paid for. The CapEx spend on that space is already done. So as more and more customers come in, you'll see that we'll get operational leverage that will help our financial position. If you look at the market again, the top three have decent penetration, but a lot of the market is unconsolidated. If we wanted to deploy more CapEx, which we will, we can deploy more CapEx into the white spaces and be in a position to grow our business further. So we've got multiple areas that we can actually scale our business, both in Healthcare Services and in Diagnostic Services. We're very positively placed. If you look at the lab side of our business in Romania. Again, we've invested, we're very strong. We're very strong. And you can see there are lots of white spaces there on the left hand side. We've grown our business very well. Our test volume is up 5%, our revenues are up 10%, and our profits are up 15% in the country over a couple of years. We're a big Fee-for-Service player. We're very, very trusted members of the public who want to ensure that if they spend money with you from a lab perspective, the test is done and the test is done well. And we have a very wide portfolio of tests available to people based upon our Romanian position, but also our German position of giving advanced diagnostics. And that helps us not only develop Romania, but also positions us to leverage our capabilities in Germany to further develop Romania and simultaneously expand into new countries. Which is the extension that we have with all of the other countries that we serve. Which we increased in 2025 when we brought in the Synlab SEE portfolio to expand the network. Again, more volume goes through that network. It's very productive from an operational leverage point of view. So we've got good product development, we've got good digital tools, we've got good procurement, we've got good distribution, we've got an excellent platform to grow. So Romania is an attractive healthcare market with strong Fee-for-Service segments. Healthcare is coming out of a big phase. Our healthcare division is coming out of a significant phase of investment, which means that we are fully invested to serve customers entering our facilities. That will be very positive for our business model and diagnostics, driving a very strong fee-for-service segment, balanced with not only our developments in CEE countries, but also with the platform we have of distributing via doctors. So a very positive position from a Romanian perspective. And finally, we have India, and of course, India in terms of shape, size, and scale completely outweighs Europe. If we look at not only the countries we're in in Europe, but the whole of Europe. So if we look at the states that we're currently in, the population within those states is the size of Europe. It's a massive country, massive opportunity. If you look at the outlook, all the indicators are extremely positive. GDP growth is 6.6%, healthcare market growth is 7.6%, and the private market is also robust. It is 13%. If you look at it from an OECD perspective, you've got a massive gap, 19 times in terms of India's spend per capita versus the per capita spend of those countries. When you look at the key insights and say, what's the size of the market? You're talking incredible numbers, 68 billion market, 13% market growth of 30 billion. And then you look at our market share, and of course, we look small, but we're a significant player. So the macro outlook for the country is very, very strong. And it's very strong for us in terms of looking at the potential opportunities to engage with consumers. Because if you look at the disposable income and the trend of disposable income, people in India are getting richer and richer. People are earning more and more money. If you look at the gray, the blue, the dark gray, and the darker blue, you can see they're all growing. More and more people are moving into the middle classes. As more and more people move into the middle classes, they get choices. If they get more choices, one of those choices will be about where they get their healthcare? How is their healthcare delivered? We're ideally placed to be able to support that journey. And of course, the population is aging. India is an incredibly young country. It's an incredibly young country. But of course, as the population ages, their need for healthcare will increase. We will be there to support that particular need. And if we look at the investment that we've made in recent times, we've made a tremendous investment in healthcare space. You've got 66,000 m² of extra space that we've put on since 2022. And if we took that further back, it would be even bigger with the extra hospitals that we've put in place. We've changed our mix of hospitals. So you've got a few pluses and a few minuses within the mix, but we've still got a big footprint and we've got a lot of operating beds. In terms of total beds, it's bigger, but in terms of operating beds, we've got a lot of operating beds. And you can see, in the middle section, as we've put that capacity on, our revenue per square metre has dropped and our occupancy and our utilisation has dropped, which is the pie chart on the right-hand side, which is below 50%. Now some people will say that's bad news because everything's dropped. But actually it's excellent news for us because as time goes by and this space gets filled, there'll be a tremendous difference in the business model that we have within India. And we've currently reached a phase where our major investment has now stopped, and it's time to fill this space with more customers and increase the utilization. There's no shortage of opportunity in terms of further expansion. It's not our focus at this moment in time, but you can see the market is mainly consolidated. We operate in four key states. You can see those key states with the graph in the middle with the blue concentration. And you can see in terms of the number of hospitals we have within three of those states, it's very comprehensive. We are a big player in these states. We're a major part of the healthcare delivery. And these states are very, very attractive. It's in a very attractive place to be within India. Because 30% of the GDP of the whole of India is within those four states. As I said earlier, the population is greater than the population of Europe. And if you take just Hyderabad itself, Hyderabad itself, which is where our main activities are, you will find over the course of coming years, the population of that city alone will increase by 5 million. And as that increases, it means that we've got an opportunity to fill the beds that we have, but also to put on more beds. And if you look at the gap of beds across the whole country and you look at what is the demand today and what what is the gap? The gap is somewhere in the region of 2.5 million beds. So, in terms of the capabilities on the ground versus population growth and the increasing middle classes, there's a tremendous opportunity from an Indian perspective. And if we look at that from our own footprint perspective, we've got some really good indicators or really good trends that will help our business develop and help us move positively towards our financial targets. One is the increase of beds that we've put on recently in tier one cities. There is a massive difference in tier one cities in terms of the average revenue per occupied bed versus the average revenue per occupied bed in tier two or tier three cities. And a lot of our development in recent times, both over the past three years and prior to that, has been to put more capacity into tier one. So we will get a natural increase of our average revenue per occupied bed as we fill our occupancy in terms of the space that we've put on, and with that extra revenue per occupied bed that will drive business growth, that business growth will come through in operational leverage. And we'll see that both from a top line and a bottom line. And of course, a lot of our assets are immature. So if you look at the bottom, what assets do we have? How mature are they? How will that mature over a period of time? We've got a lot of new assets, which means that they take time for customers to come. It takes time for us to attract the doctors. But over a period of time, what we have seen is that it matures, and our occupancy increases. As our occupancy increases, our business model improves. And we have another very big advantage in India, which is our digital stack, which is our technology. And in India, we're 100% mobile. There's no paper. So if you come into our hospitals, you won't find nurses running around with files. You won't find doctors coming in with a big paper file looking at things. He'll come in with his phone. Everything that our doctor needs to be able to treat you as a patient outside of the operating room, of course, is in that phone. So he can basically navigate our complete healthcare system with that phone, including if he's unhappy. So if one of our doctors is unhappy, he can simply say it through the application. It will go to a supervisor. That supervisor needs to react within a time period. If they don't react within that time period, it will go to the next level of supervision,etc. And so on. until it's completely resolved. And that's the same for our customers in India. If our customer goes into the hospital and there aren't towels, or the bedding isn't right, or there's something they're unhappy with, we're immediately on the spot to solve all their complaints. All of our capability is within our technology, and all of our technology is digital and on the mobile. So, we have a complete, very efficient way of dealing with all of the patients. That leads to a much greater focus on the way that we care for people. It allows, from our business model perspective, for our revenues to be tighter. If a customer comes in and they need a scan, the person who will conduct the scan is immediately aware of this need and can promptly attend to the customer, guiding them through the procedure. This makes the scan better for the customer because they get their service very quickly. Better for us because they can't walk out of the hospital and say, 'I don't want to have this; I'm not going to have the scan.' I'm not going to have the scanner. I'm going to have the scan somewhere else. So we have a very, very powerful technology stack that we have available in India. A doctor says, I'm going to operate on a Monday. That means that the outpatient room they would use cannot be booked by them, as we know they're in the operating theatre. They can't have the room. That means we achieve optimal efficiency in utilizing all our space. So, this is a very positive position. And if we look at India, it's a really, really big market. We're really, really well placed. We've got a lot of capability there that we've already invested in. As that fills up, our business model will improve and things will get stronger. And finally, my last section addresses technology. Technology is a really important part of the future when it comes to healthcare, both from a customer perspective, both from a doctor's perspective. Some of the things I've just talked about from an Indian perspective will be needed and required in our other markets. People want to deal with things straight away. People want to be able to book things straight away. People want to be able to see their medical records straight away. They want to see their results straight away. They want access to the doctor to ask questions. They want to be able to be empowered and guided through the system. We as a provider want to see what our customers are asking for. We as a provider want to understand what our customers are not getting. We want to understand where they're frustrated. We want to understand where they're completely satisfied and engaged. The technology stack helps us understand that and develop new services. We have got a long history of being able to develop technology. We've built all of our capabilities on being as efficient as possible, and this has driven a lot of trust with our customers when it comes to our technology. They know that they can use it. They know that it works. They know that it makes an impact, and digital is a big part of our core. There are many things that people talk about today. Things like electronic medical records, results online, booking appointments, getting prescriptions, all these types of things. We've been doing all of this stuff for a number of years. People talk about virtual care. People talk about virtual care accelerating as a consequence of Covid. Covid didn't affect us, didn't affect us at all. We had all of the capabilities to be able to change our services the next day. We didn't have to build anything. We didn't have to do anything. We just executed. And our technology stack and our engagement with customers in our core business is really, really strong. 88% of our members have our application, so we are in their pocket when it comes to healthcare. Those people have us walking around with them. And when they have a healthcare need, all they have to do is bring that out of their pocket and start engaging with us in terms of what they need and what they require. 75% of our bookings in our core business are done online. People are not going to our receptions. They're not going to call centers; they're not in queues. They're basically sitting there themselves, deciding what they need and when they need it. Looking to access it. And in our primary care services, as well as many other online offerings, 63% of interactions can often be completed remotely, which is incredibly high. Having those relationships, having people in our technology, having people engaging with us allows us to get deeper relationships. If we get deeper relationships, it's harder to move away. If you get deeper relationships, it's also an opportunity for you to be able to say, let's do more together. Let us care for you more together. Let's offer you more together. And of course, it drives a lower cost of servicing because instead of the call center people answering the phone, our customers are doing it themselves. So we're very, very well placed. We intend to develop that further over the future in terms of different solutions for patients, different solutions for medical professionals, different solutions in terms of our operations people. And of course, we intend to make it much more integrated. We intend to make it much more connected. We intend to make sure that the customer stays within our system, and that we are the people looking after them. So in summary, we've got a great opportunity. We've got some really ambitious targets, which we're really excited about, which we're looking forward to delivering for you over the next three years. We've got 90% of our business in our four key markets. We've got four very attractive markets. We've got four markets where we've got really strong business models. We've got four markets that are really developing well, and we think that we're well placed for the future. Thank you very much for your time.

Matthias Waldstein
53:49 - 54:31

Thank you very much for that thorough run through, John. We will now go ahead with some Q&A. It will run until 2:15 p.m. Just to remind you of the process. Those of you that are in the room and want to ask a question, please raise your hand and we will provide you with a microphone and you can ask a question. Those of you attending online continue to submit the questions in the chat. So with that, I think we kick off the Q&A session. Maybe one question from me first. Sorry for being too much of an analyst here, but looking at the chart with the contributors to the 2028 revenue, Germany was a bigger chunk than I thought.

Unknown 5
54:31 - 54:35

They were the same. We purposely made them the same. Yeah.

Unknown 2
54:36 - 54:36

That's good. Yeah.

Matthias Waldstein
54:37 - 54:50

But when it comes to that, maybe a general sort of zoom out question to begin with, in terms of the contribution to these revenues, how do you perceive Germany in that respect?

Unknown 5
54:50 - 56:06

Germany is a big, stable market, is Germany going to be the biggest driver of our growth? Probably not. Yeah. Is Germany a very important part of our growth? It certainly is. Whenever you look at our markets, especially our top four, you know. So, Poland. Big opportunity, big growth figures. You go Romania the same. You go India, well, even more. And then you go Germany. Well, that's pretty stable. And then, when you look at the increasing middle classes we've got in all the other countries, the dynamics in those countries are pretty much the same. And in Germany it's not. But what Germany provides for us is a very stable business. It's got a really good footprint, which is well established, where customers appreciate what we do. It's got two very interesting development areas that are national and international, some of which we've already deployed internationally within our own network, which is really, really good. So I think it's an important part of our future and it's an important core component. But I appreciate when people look at the dynamics, it looks a little bit different, but it's an important part of what we do.

Matthias Waldstein
56:06 - 56:15

Definitely. And I guess a question that's typically being asked in the recent two years relates to the perhaps challenging environment, particularly with the reform.

Unknown 5
56:16 - 56:17

I mean, sorry.

Matthias Waldstein
56:17 - 56:22

Just if that opens up sort of opportunities for you as a large-scale player.

Unknown 5
56:23 - 58:10

I've said similar things over the course of the last 12 months, which is reform is good and bad. You know, reform is challenging to begin with because we have to navigate it. We need to navigate it, understanding what it is. What do we have to do? How do we navigate. It becomes the focus of the day, but reforms are also good because it challenges you to change your business, and you have to do things that maybe you didn't do before, and you have to do them with a greater sense of urgency. And particularly in Germany, navigating a sense of urgency can be quite hard. You've got all of the work councils that you've got to go through. You've got to get a lot of stakeholders lined up to be able to move things forward. I think what we've done very successfully, and congratulations to the team, is that they have navigated that first year of reform. We've done four quarters and come out of it positively. We've probably got a fifth quarter to go because of the settlement factors. That needs to happen and reform lasts much longer. Sorry. The transformational change that you put in place lasts much longer than the reform itself. So the benefits that we'll get of that will go on in further quarters. And then of course, any reform tends to chop off the tail of supply. So the bigger players tend to be able to navigate reform. Yeah. The smaller players tend to find that it's harder for them to navigate that reform and they fall away. And then some of those smaller players for us could be an opportunity in terms of picking things up, or they fall away. And the customers that used to go to location A now need to go to location B and will be one of those location B's. So, I think in the first phase we've done well, and in the second phase we will have to wait and see what happens.

Matthias Waldstein
58:13 - 58:24

Maybe switching gears to Poland a little bit. Indeed, looking at the past 15 years, it's been strong market growth and strong execution from Medicover.

Unknown 5
58:24 - 58:25

It's because I joined.

Matthias Waldstein
58:27 - 58:41

That's a give or take. You have doubled the growth of the market. So just put it in perspective a little bit. How challenging is that and how difficult is that to keep up the pace that you have.

Unknown 5
58:41 - 60:28

The market's not soft when it comes to competition. I don't think the market will get any softer when it comes to competition, especially in the next cycle. If interest rates drop, there'll be some old competition that disappeared for a while coming back in terms of funds and stuff, which will make it a little bit more interesting. We've really developed a lot of capabilities in many different parts of healthcare delivery, from pre-birth all the way to hospitalizations, and all the things in between. We've made sure that over that period, we've tried to offer value to and look after the customer; when it comes to things like price increases, we haven't shied away from putting the right price increases in so we can retain the quality as we go along. So we've got a really strong brand. We've got a kind of landmark brand. People come to Poland and say, can you take me to so and so location. It's right by Medicover. And we've earned that by the delivery that we've done. And we've got lots of opportunities in space to grow. And the team are quite excited about new products and new developments. We've recently gone into things like Sport and Wellness. Sport and wellness, which has gone fantastically well. And there's other spaces that we feel we can go into. So whilst the environment will change, driven by government, driven by competition, driven by consumer behaviour, we think that we've got a really strong competence in the team, really good leadership, really good opportunity to be able to navigate what comes at us and when it gets difficult. I think that's when we show our true colors. We have to adapt and we have to adapt fast, and we do that. Well.

Matthias Waldstein
60:28 - 60:54

And just on what you just said there, there are further spaces to move into and so on. And you have clearly shown that in the recent couple of decades there are more opportunities in Poland. So just discuss that space of opportunities a little bit. And then I have another question, though. With the success story in Poland, could you move some of the services into Romania or another country?

Unknown 5
60:55 - 62:36

In terms of your first question, what spaces are and where to go, we're not short of opportunity. Yeah. So usually what holds us back is more like management competence, meaning if we're going to a new space, we've got to be careful because we need it to work. We want it to work. So we've got to get the right competence in place, but also in our core, we have so many different opportunities within what we currently do. Developing that faster is probably our current focus. We'll do and as that gets stronger and stronger, then it gives you a license to explore some of the newer opportunities. But we'll do a balance of both. That's really what we'll do. And when it comes to things like people ask quite regularly, what about the sport and wellness? Will you take it to places like Romania? Currently we've got a lot of growth to do in Poland when it comes to sport and wellness. We've got 176 gyms. Our major competitor is sort of saying they're going to go up to 400. We don't have to go up to 400. We just have to stay relevant. And I know exactly the position so far in the dynamics, and so does the team about how many do we need to stay relevant and continue to take market share? So, we'll stay very focused, I think, over the three-year period to develop healthcare in Romania and our broad proposition in Poland. The core 90% will be where we focus, and most of our activities will be in what we do today, with a little bit of license to go into some new space for the future.

Unknown 2
62:37 - 62:38

Good.

Matthias Waldstein
62:39 - 62:43

Any questions in the room right now? We have a question here in the front.

Unknown 3
62:47 - 63:07

But we'll do a balanced move of both. Good to see those slides on the capacity. Capacity utilization? Is it possible to share your targets for improving that in the context of your ambition for 2028 sales and earnings?

Unknown 2
63:07 - 63:07

Yeah.

Unknown 5
63:08 - 65:15

It's impossible to give you a number. Because you've got many different assets, many different locations, etcetera, etcetera. But if you take India as an example, because that's probably one you're more interested in, for our India plan to work successfully, we've got to do a double-digit percentage increase in those locations for it to move up. And, you know, in our model in India, from a financial perspective, that once you get past a certain point, because we're very much a fixed cost model, the model becomes very, very sweet. And, you know, our focus in the last probably five years really has been about taking some really good opportunities to build the scale. And we've built the scale. And now we're entering a slightly different phase, which is that we're not looking necessarily to put on more hospitals. Although you can never say never if an opportunity came up. But it's much more about how do we fill up the space, and there are three levers to do it. There's three things that count, which is doctor recruitment. Doctor retention. Yeah. Which has been a real big focus over the last six months. Nine months. As a consequence of that, the occupancy going up and then, within the occupancy, the average revenue per occupied bed. Right. And as I alluded to on the slides, we'll get a natural increase in our average revenue per occupied bed by the fact that we're going into much more tier one cities, and we stated many times that we need to repurpose from being tier two, tier three into tier one. But even within the tier two and tier three, we've got a bit of a price advantage in some locations. And as insurance builds, we may find that within those locations, we have a good opportunity to not only fill occupancy, but increase average revenue per occupied bed.

Unknown 3
65:16 - 65:19

So what do you say is somewhere 60, 70%?

Unknown 5
65:19 - 65:28

Yeah. Once you get over the 60 mark in India, it's. You feel it? And then in Europe, it's a lot higher.

Unknown 3
65:28 - 65:43

And regarding your comment about possibly slowing down on investments in India, do you still want to keep total investment or total CapEx as a percentage of sales? So what markets will you prioritize here in the next coming years?

Unknown 5
65:43 - 66:12

Most of our capital will go into our top four markets. And of course, we've developed India very well in recent times. We've had a focus on it. We've developed our sport and wellness very well in recent times in Poland. I think we can easily deploy more capital back into our medical business in Poland to fuel much more growth and strong profitability. So, we intend to make sure all of our key markets move forward.

Matthias Waldstein
66:14 - 66:20

We've developed our Sports and Wellness very well in recent times in Poland. Maybe a follow up to that. Is the competition more intense in the tier one cities in India?

Unknown 5
66:21 - 67:30

It can. It's different dynamics, really. It's not one of those things where you should sit there and say tier one, tier two. This is the way it works. It's city by city, location by location. So, your population in India is so big in the immediate catchment around where you are that a lot of the competition is about who's close to you, which hospitals are close, and don't underplay the retention and recruitment of doctors. It's a really important part. And we've had times when that's hurt us a little bit. And in recent times we've really, really focused hard on it. And you'd have seen a bit of momentum that's come through in recent times. Q4 14.7% growth, local currency. We expect that to continue from the work that we've done. We're at the business end when it comes to the IPO process. Everybody in the room knows that we've got to increase our revenue growth to be able to be in the right zone at the right time. And that's where our focus is. So it's going to be an interesting few quarters.

Matthias Waldstein
67:30 - 67:33

Good. I think we have another question from the audience.

Unknown 4
67:34 - 67:52

Yes. Or it was actually on competition in India. So maybe just rephrasing it and a little bit broader. Given its huge market potential, how should we look at competition in relation to markets in Europe?

Unknown 5
67:53 - 67:54

In what respect.

Unknown 4
67:54 - 67:58

Is it much tougher than, for instance, in Poland.

Unknown 2
67:58 - 67:58

Or okay.

Unknown 5
67:58 - 69:37

Okay, India can be cutthroat. There can be times when it's really, really cutthroat. So what's really important for us and any player is that you recognize what's going on really, really fast. And as a consequence of that, you take action really, really fast, and that you're agile, that you don't have a position where this is our fixed model. Let's not keep with our fixed model. We've got a really good operating team in India. The capabilities they've put in place are really smart, because what they've done with that technology stack is that if they were to build a really big business, they can't be the people dealing with the doctors all the time, and they need to make sure that the doctors still get really well served and looked after. And looked after from a complaint perspective, and also from a technical standpoint. What technology do they need? What environment do they want to work in? What support they require, all this type of thing. So our doctors can all the time say what's required. And we respond very, very quickly. So, the recruitment and retention, the facilities that we give, the kit that we give, the fact that we will pay them on time—it sounds stupid, but people are getting paid. This will drive a higher degree of doctor retention. And from that, that will really help us grow. But it's cutthroat. It really is cutthroat. But we've got a great team. Don't mind it if it's cutthroat, if you've got a great team, because they can move and take advantage of the spaces in their environment. They never stand still. They never stand still. They're very challenging and demanding on me. And long may it last.

Unknown 4
69:37 - 69:44

And they are looked after from a complaint perspective and a technical perspective. And just a short follow up there. Would you say that competition has increased a lot over the last years?

Unknown 5
69:44 - 70:42

And they are looked after from a complaint and technical perspective. So India has become a hotter subject in healthcare in recent years. So, more people are interested, and more people want to play. If you actually look at our hospitals and go through the history of where are they? How did we get them? What was the history of who owned them before all this type of thing? It's an absolute graveyard of people that thought coming into healthcare was really easy in India. Look at the dynamics. Loads of beds needed. Let's just put the beds out there. We'll get the customers. Everything's going to be great. And the reason that we've been able to build such a great network with low capital is because we've come along afterwards and swept it all up, and then we've sorted it all out. The local team has sorted it all out. So, more people are interested, but we've managed to navigate. I'm sure we'll navigate as we go forward in the future. Interesting time for India.

Matthias Waldstein
70:45 - 71:04

Good. I'll get along with the question. One word I caught from the presentation was that the segments are highly synergistic. So, maybe a discussion around that. I would say Romania is where you perhaps have a significant presence of both segments within the country.

Unknown 5
71:04 - 71:04

Yeah.

Matthias Waldstein
71:04 - 71:07

So just how investors should perceive that.

Unknown 5
71:08 - 72:59

Poland is probably a good example. Really. Historically, the model in Poland involved very focused verticals, with teams dedicated to specific areas. We did that because we didn't necessarily have the competence in each of those verticals. We needed to attract the right competence. We wanted to build that competence. We had opportunities to buy lots of things, so we needed the management teams to be able to be there to buy lots of things. I think now we're reaching a different phase, which is, we built the competence, we've bought lots of things. Now we need to bring things together. And as you bring things together, you do become highly synergistic. We've already got natural synergies from the fact that when you've got healthcare delivery, you've got testing that's done. Our Polish business and our Romanian business do a lot of testing, which all goes back into our own facilities. And probably we haven't used our property footprint as well as we could have done in history, which is that we've got a property there that does X and all it does is X. And we really think that when we look at our large property portfolio, with its many points of sale and service, while we currently offer services there, we can significantly expand our sales presence and showcase our full capabilities. So, synergies is a word that we would like to hear more of internally in the business and how we do things together and how we create new things together. And that may not actually be fully executed in this three-year cycle, but we have some great opportunities, like genetics, which could take a little longer to achieve full execution but represents a really big opportunity for us.

Matthias Waldstein
73:00 - 73:02

We have a question in the front.

Unknown 3
73:05 - 73:33

Two more, if that's okay. Interesting what you say about this upsell potential. Upsell potential at the Romanian hospital. Is it possible to qualify that in a way, or quantify it? And is it so that most patients showing up at the hospitals there have some public reimbursement to start with, and then they add to that? Or how does it work?

Unknown 5
73:33 - 74:26

Yeah, it tends to work in that way. So, the model tends to be that there are certain services that a consumer will pay totally out of pocket for. While there are some services, most involve consumers accessing the national fund; however, it is recognized by both the fund and the consumer that the fund's average payment for the service will be too low, requiring an additional contribution from the consumer on top of that payment for their care. So the more national fund development that you can do, then it naturally drives a higher Fee-for-Service volume in the country.

Unknown 3
74:26 - 74:28

And what's the typical split between?

Unknown 5
74:29 - 74:30

Depends on procedure.

Unknown 3
74:30 - 74:30

And that may not actually be all executed in this three-year cycle, but we've got some great things like genetics that could take a little bit longer to get full execution to bring it together, but it is a really big opportunity for us.

Unknown 5
74:31 - 74:45

Probably the easiest way to mentally think about it is let's say that the fund is paying for the hospital services and then the consumer is paying for the doctor. That's a mental way that they deal with it.

Unknown 3
74:46 - 74:58

One more question. Germany and the diagnostic business. You showed how the number of tests has increased in the last two years despite the reform there. What could you say about profitability?

Unknown 5
74:59 - 75:01

Yeah. Yeah. It's okay.

Unknown 3
75:01 - 75:06

How is it, are earnings up or down?

Unknown 5
75:07 - 75:07

It's okay.

Unknown 3
75:07 - 75:08

It's okay.

Unknown 5
75:08 - 75:10

I refer to my previous answer. And that may not actually be all executed in this three-year cycle, but we've got some great things like genetics that could take a little bit longer to get full execution to bring it together, but is a really big opportunity for us. Yeah.

Matthias Waldstein
75:11 - 75:54

Okay. Thank you so much with that. We will do a 15-minute break. I think there is coffee and water. And those of you joining online, make sure you have a stretch and be back in 15 minutes for our next session. We will do a 15 minute break. It's 2:30 p.m. now. Jess. Welcome back everyone. It's 2:30 p.m. now. It's time to continue with the session here. We have the great pleasure to introduce Anand Patel, CFO of Medicover, who will walk us through the financial highlights. And after that, we will have plenty of time for Q&A. So with that, Anand, welcome.

Unknown 5
76:10 - 87:36

Hello, everyone. Thank you for those attending in the room and thanks to our people listening in online as well as participants. John and I appreciate the time spent with you today to explain our exciting business and plans. I guess in terms of my slides, just a couple of things. So one, I'll talk about the history of the last three years. Two, I'll touch on the recurring themes that we take forward into outer years. And finally, I'll end on the 2028 plan. So, in terms of what we've done in 2025, and even before that, actually, if you think from the IPO launch, Medicover has set external targets three times. Aside from the ones we're going to be doing later. And all three times they've exceeded those targets. So this is a company that has a track record of delivery. So if you look at 2025 in particular, for example, John and I reported on these results yesterday, you can see that we've grown our organic revenue by 15.5% to over 2.2 billion. Material and accelerating growth in EBITDA to 369 million. We operated within our leverage and dividend targets. And finally, for the incremental measures that we added on later because they were asked for to better explain our valuations, we beat those as well. I'm particularly proud this year of the EBIT number of 156 million, a material step-up. And also, our EBIT margins were very strong as well. So again, three times the company in the past has said we're going to do something. Three times we've delivered. We do what we say we're going to do. Looking at adjusted EBITDA in particular. You can see that the rate of our growth is increasing as well. Maybe there'll be a similar theme for when we look up to the 2028 numbers. There's been growth and we've accelerated our margins as well. So we've always historically, John and I have said that we invested in a lot of space in the past that led to muted margins for a while. But in FY25, you saw the flow-through in the margin rate, particularly from those investments, which were worthwhile and considered disciplined. But actually, they're paying through. So in terms of the growth of adjusted EBITDA, 16.4% faster than our revenue, clearly implying increased margins. We are scaling capacity and also creating further headroom. This is a slide on margins. And I think the other thing I'd touch on this slide is about the medical space. So if you look at the organic medical space (the organic version shown in the light blue boxes), you can see that we've increased by about 13% to 920,000m² by the end of 2025. So we've invested, but still growing our margins. At the same time, we haven't grown our margins by cutting costs. We have invested in the right things, and our margins flow through regardless. So irrespective of whether through price or volume growth or investment in business units that we acquire, organic or external, we've just seen the steady flow of improvement in our EBITDA margins. So that's pleasing to see, and we'll see more of that in the future given the numbers we have. It's a VUKA world, right. As we say, there's a lot of headwinds against us and our competitors on a variety of issues. You've heard us talk about a lot of these in terms of workforce, getting the right people whilst you grow. Inflation's been there. Can you price in inflation and still grow the business? And obviously we've spoken a lot about Germany in terms of public lab reform in the past. But what we do have is a tremendous team with a lot of experience that really pulls on either the right revenue levers, the productivity levers, or the cost levers to see off those headwinds and provide efficiencies and opportunity. So I'll touch on a few of the comments on the right. So, from a revenue mix perspective, you've seen that in the past. And John said earlier that we have opportunities in the future to move to more fee-for-service funding or revenue payments in certain countries. We'll continue to do that where appropriate from an organization and workforce optimization perspective. What we have done. So I'll give you a very simple example. For some general or minor doctor practices, we enable nurses to perform them under certain legal requirements. That affects us in terms of optimizing doctor time to focus on higher revenue-generating items, whilst optimizing the cost of the nurses. So we've got a terrific team that does things like that from a cost and productivity perspective. As the market in Poland has grown in particular, we are scaling our operations there. You naturally get the economies of scale in terms of your purchasing. So that kind of flows through into the numbers, and we see further growth, as John said, exciting times for Poland in the future as well. We should hopefully leverage even further cost opportunities. And finally, John gave a lot of praise to the Germany team today. Absolutely great. Hats off to them. They've dealt with the reform over the last two years, we've carried on growing volumes, although clearly there's been a price cut as we've seen. We showed there's been an increase in revenues and we have improved our EBITDA margins as well. This is a team that faces adversity in terms of headwinds and comes out with a superior result on the back of it. Although we've invested, I'd say we've been quite disciplined in terms of our investments. And what that has meant is actually our cash flows materially improved as well. So, as I mentioned yesterday, the real key point for me in Q4 was very good. But if you look at the full year for Medicover, our free cash flow as a percentage of revenues was up to 7.1%. We are generating more of our earnings into cash. That's a good news story. From 4.8% and 3.2% three years ago, which wasn't that long ago. And this, clearly, even after deducting our organic investments in CapEx, offers a clear white space opportunity that naturally provides more cash in the future and gives us pleasing options. You'll have seen our invested capital worked harder as well, so we reported yesterday that our ROIC was up to 13% on the back of investing, actually not cutting costs or stopping investing on certain things. So there's been a big jump, particularly in 25, you'll know, because at the end of 24 it was 6.7%, showing a significant increase this year. We expect to improve in the future given some of the initiatives that John spoke about earlier. And from a shareholder perspective, I think we strengthen returns to our shareholders. So, EPS, another number. I'm proud of that. We reported yesterday over €51 cents, up from $0.11 last year. And over time in a controlled way, we've increased our dividend per share. So you'll have also seen yesterday that we announced that the board approved a €20 cent dividend for AGM approval, which hopefully will be done at the AGM in April. So again, strong returns for our shareholders whilst we grow our business. In terms of financial discipline, I think you'll know. You'll have heard we bought quite a few businesses over the years. There have been lots of investment phases. But actually, we said we'd operate under three and a half times, and we have. And that's despite the fact, if you think not that long ago in Q2, we bought two of our biggest acquisitions in history. Right. Totaling nearly €200 million. After that, from 3.6 to 3.1 in half a year just shows the strength of cash flow that we're driving. So remarkable. It was really pleasing for me to be part of a business that does things like this. Makes my job very easy to talk about when I stand up and talk to you guys. So in terms of the common themes and I'll just touch on them again, I've said it before. We do what we say we're going to do. That's one. We accelerated our cash flow. We enhanced shareholder value. We kept CapEx at around 6% over the last three years. We'll probably keep about that percent going forward. But equally, there have been headwinds, and there will be headwinds in the future. But we've got a team and processes that mean we face those headwinds and come out stronger. So if you look forward and some of these repeat what John said earlier. So I'm not going to keep going on about them. We'll drive more cash. We will continue to invest in capacity. So I mentioned that we'll spend around 6% of our CapEx in the last year or so. You could argue India's got a disproportionate amount of CapEx versus the revenue it drives that will normalize now as we wait for the benefits to come through in terms of capacity utilization in India, and CapEx will be rebalanced to other areas where we see further growth and there are opportunities. We do believe there still is scale in terms of cross-country synergies. So there is a bit on that and also intra country as well. So from my perspective, we bought quite a lot of businesses over the last 2 or 3 years. We haven't fully integrated them yet. You buy a business; you buy their finance team, their systems, their operations. There's value to be generated by integrating it within the Medicover model as well. So there are opportunities there. John spoke earlier about improving utilization in India and Romania. We can see that happening, and we're focused on that. It's stepping up a little bit quarter on quarter. And finally, as a consequence of all those things, results will go up, and margins will go up. And despite all that, we're still targeting double digit revenue growth. So after a long period of double digit revenue growth and growing margins, we're going to be doing much of the same in the future. So very pleasing for us. And then now onto the new targets. So I'll pause for a minute because I know you've seen them already yesterday. But we believe they're ambitious. We believe they're challenging, but we believe in the strength of our business that we can deliver them. So organic revenue in excess of €3.25 billion. That's double digit growth. Organic EBITDA in excess of €600 million. Again, a very strong dividend policy, broadly the same as last time. Leverage we've reduced from three and a half to three. That doesn't demonstrate any lack of ambition in our business. It just demonstrates we're driving a lot of cash that gives us options; if we need to exceed three because there are good opportunities, then we reserve the right to go over that for a short period of time. You can see the bottom two illustrative measures that I've touched on in the past with regards to adjusted EBITDA in excess of €430 million and EBIT in excess of €290 million. So we talked about the EBITDA margin of roughly 16%-16.5%. If you look at the EBIT, and I'm sure some of you already calculated that, that's 23%. So, if you believe these numbers, and we've achieved our targets in the past, we are driving a significant amount of EBIT, which drives a significant amount of net profit into our business. So not just focusing on the EBITDA but across all the profit lines, the numbers look better. So that's it from me. I am very proud to stand here and talk through these numbers. I'll be very proud in three years. It will be time to stand here and say that we've delivered the numbers. But in the meantime, I think it's over to us for some Q&A. I think, I'm very proud to stand here and talk through these numbers.

Matthias Waldstein
87:53 - 88:36

Thank you for that, Anand. It's now time for the final Q&A session. A bit longer. And I'll just remind everyone once again that if you do want to ask a question, please raise your hand and ask for a mic in the room and online. Keep on adding the questions to the chat. I can see we have quite a few already, which is which is good. And with that, I think to kick off this Q&A session, M&A has been a core part of Medicover journey as long as I've been looking at it. At least you've added some 5% to revenue growth, I think via M&A in the longer perspective. So yeah, how is the pipeline?

John Stubbington
88:37 - 89:52

It's good. We've got a good team that are constantly developing it and looking for the right opportunities, and I would rather look for some bigger opportunities similar to what we did in 2022 because the big deals, big deals for us because they're the two biggest we've done, make the most sense. But of course, they don't come up every quarter. And of course, we have spots in our network which we can cover much more efficiently by buying than building. So you'll see us being active; it's a constant kind of process. People will say, well, what are you looking for? We very much want to expand our hospital network. We very much want to expand our clinic network, our sports and wellness network. We want to expand our lab capabilities, which are important to us, so we need to look at that as well. But we think we've got some good opportunities. And, over time, you should see that we're announcing we've done this and we've done that. So we're very active.

Matthias Waldstein
89:52 - 89:59

Good. Would you highlight any particular areas that are of maybe more interest than others?

John Stubbington
89:59 - 90:48

Yeah. Sport and wellness. We have to stay relevant. You know, when we made a decision in Poland to go into that sector, we were taking on a very dominant player, and to take on a dominant player, you've got to be relevant to their dominance. Yeah. So we've still got to remain relevant there. We'll do some of that organically, some of that inorganically, clinics and hospitals. It's the same as I said before, really. They're really the important things for us at this stage of our cycle. But as an organization, we're entrepreneurial. If something came along that made sense for us, never say never. Our focus at the moment is on the core. But let's see what happens.

Matthias Waldstein
90:49 - 91:06

Yeah. And maybe a question for you. And you talked about the role ROIC in the presentation. It's gone up quite a lot. So you talked about the general trajectory going forward, but could you say anything about internal demand on projects you do on ROIC terms or where you aim for?

Unknown 5
91:07 - 92:23

So I am pleased that in my first year, it has gone up significantly, which was not the case in the first few years. So there you go a little bit from an ego perspective. But look, I think we are clearly a healthcare company. Providing quality healthcare is our priority. But fundamentally we have to be a profitable business in order to do that. So we have a very strict regime in terms of assessing the opportunities that come to us. Because if we generate returns on the back of that, then we can provide more healthcare. Square meterage, which serves people. So I'd say we've got a robust process in terms of future outlooks for ROIC. I'm not going to guess it. You can imply the margin rates on EBIT and EBITDA from the numbers that we've given today. I'm not saying they'd be right, but they'd obviously be ballpark enough. Look at what we got at the moment. And you can kind of extrapolate where roughly we would end up. Right. Particularly given the fact that we've said that leverage will be where it will be as well. So it'll be north of now. But, as you say, I think what will happen. But that's on a like-for-like basis. If you let our current existing units mature, we will buy things which may kind of dampen it in the short term, but as an ongoing basis. But we will only do that if we believe there's value in it from a monetary perspective.

Matthias Waldstein
92:25 - 92:45

That's a good answer. I think as I'm asking the online audience to ask questions all the time, I might as well take a few questions from there, please. And here we have one with respect to the 2028 targets, is there a back or front-end loaded nature to it, or should we assume a more steady and linear progression?

Unknown 6
92:46 - 92:46

Over to you.

Unknown 5
92:47 - 93:05

Yeah. Look, I think if you look at the last three years, it's been a bit of a hockey stick, so I would model something accordingly. Otherwise, we'll have constant calls in the next year about why you're not demonstrating that trajectory. That's not to say that it won't be, because we are actually doing actions now. But yeah, I would kind of back end some of the benefits.

Matthias Waldstein
93:07 - 93:20

Good. And we have, I'll move on to another one. Please update on the IPO of the Indian subsidiary. What's the status? When do you plan to go ahead, or do a go no go decision?

Unknown 6
93:20 - 93:21

I'm not going to guess it.

John Stubbington
93:21 - 94:58

So, let's just put it into context. December 12th, 2024, we announced that we would explore doing a listing in India. And we put a long time scale on it because we knew we had to do a lot of preparation work. We've done all that preparation work over the course of 2025. We're now into what I call the business end of the IPO process. So now we're currently finalizing our advisors that are required. We know exactly the process that we have to follow. There are two key elements to it really: one is the process and making sure that our prep work was good enough and that we have the right things in place. And the second is getting business performance to maximize value. And, if we look at 2025, we started slowly, and then we bumped a little bit and then moved forward. These next few quarters are key for us in terms of the growth. So it's quite an exciting time for us with our Indian colleagues and our performance. If that goes into the right kind of zone, we're on plan. Plan A, currently today inside the organization. Nobody. We're not talking about a plan B. If somebody says a plan B, they kind of get a stern look because we're totally on plan A. If it turned out that we needed a little bit of extra time for whatever reason, because it made more sense from a value creation perspective. That 24-month period that we gave wasn't a backstop. It wasn't like we had to do it by this time because of an arbitrary deadline. But we're totally on Plan A. Yeah.

Unknown 6
94:59 - 95:00

Good.

Matthias Waldstein
95:01 - 95:30

Do we have any questions in the room right now or do you want to ask questions? Otherwise I will go ahead with another one from the audience online. So this relates to competitive environment basically. So what do you think is your major disadvantage versus Lux Med in Poland? In which area do you see room for improvement? Do you consider Lux Med entering diagnostic services as a threat?

Unknown 6
95:31 - 95:32

You know, Lux Med.

John Stubbington
95:32 - 97:22

A very respected competitor of ours. You know, we've been together, competing with each other for a long period of time. People love to say Lux Med versus Medicover. It's a natural, easy thing to do. But if you analyze the two businesses and you do your analysis in terms of the space that we're in, we're in lots of different spaces that they're not in, and they're in lots of different spaces that we're not in. And there are a couple of things that we go head to head on. Membership business is one. Quite often, they pick up slightly different membership-type businesses than we do, with a slightly different profile. So we kind of coexist. They do good things. We do good things. We do different things. Some customers go left, some customers go right. I think that that will continue. I think their moving to diagnostics is a sensible one. Yeah. You can understand it. It looks like, though we're not privy to the information, they had a historic agreement with Diagnostica when they were owned by the same people. And that agreement has ended, and that means they should move into that space. If you look at what Diagnostica has done, they've taken a lot of good space in the Polish market. And if you look at our position, maybe we could have done better. And I think now they're moving into that space. Us getting a bit more aggressive in that space will be interesting for the market in terms of the diagnostic space in Poland. So I think it's going to be a really interesting time. So, they've got good capabilities. We've got good capabilities. That's always been the case. We're going to develop new things. They're going to develop new things. Sometimes we'll go head-to-head, sometimes we won't. We're comfortable currently with the environment that we find ourselves in. Yeah.

Matthias Waldstein
97:23 - 97:40

I think that's a good, good answer to that question. I have another question from the chat here. Do you plan to enter new markets in Central Eastern Europe with your healthcare service offering, after you have entered those markets with diagnostics?

Unknown 6
97:41 - 97:42

For healthcare.

John Stubbington
97:42 - 98:48

For healthcare to work, you need scale. Yeah. And the more scale you get, the better it is. Yeah. Because then you can tailor your services. Then you can get more specialized in what you do as a consequence of getting more specialized. You get more expertise, and it tends to work. A lot of the markets that we're in from a diagnostic perspective are smaller in terms of population. But never say never. But currently we're comfortable with the model that we've got. At some stage, I'm sure that we will strategically want to look for new markets. But at the moment, you know, over the course of the three-year period, we're very comfortable with the footprint that we've got. We wouldn't rule out doing something different. But we'd have to make sure that we've got the right competence, the right people, the right expertise, the right timing, a lot of things to go right for you. You can expand into a lot of new space and lose a lot of energy. You lose. Lose a lot of cash flow. Lose momentum. And we've got momentum at the moment. We want to keep that momentum going.

Matthias Waldstein
98:49 - 99:01

Good. And maybe my next question ties into that a little bit relating to the Synlab SEE acquisition. So, just what are the key learnings from that. Have there been challenges?

John Stubbington
99:01 - 100:49

None of these things ever go by the book. It'll be brilliant. Yeah, but none of these things ever go to plan. There's always a deviation in some way, shape or form; out of the two acquisitions that we did in 2025, the Citi Fit one was a little bit easier for us to get the synergies right from day one. And they were executed well. Synlab SEE had a few challenges in terms of some of the things we thought we'd get value faster, some of the agreements that we thought we had prior to completion that some people delayed us, and then some detail that just wasn't available. At times, you can do this deal with these parameters, but it has to be done within a certain time frame. And there's only so much data to make the decision. And then when we went in and found more information, it caused a few more complications. However, what I will say is that the team working on it, whilst they went through that journey of ups and downs, they've come out of that journey well, and we now find ourselves in a position where we are close to the plan and most things are ticked off. And one of the key synergies is the difficult one, which is you've got duplication. Can you remove duplication? And sometimes some management teams avoid that because it's hard. But they executed that. So credit to that team. They were behind. They caught up. They've ticked a lot of boxes. Some of the results we had expected did not materialize. We didn't get some stuff, but some stuff that we did get is going better than we thought. So it's the normal swings and roundabouts. But if I were to be the head teacher and mark the class, they've done well.

Matthias Waldstein
100:49 - 100:56

And if you would share a few words on earnings per share accretion from those acquisitions, how do they look.

Unknown 5
100:56 - 101:34

Yeah. So I think we're not splitting out by business unit. Now you'll have seen in our Q4 report. So we'll talk a little bit more in terms of splitting the net profit impact of those two entities individually in our annual report. So we've said we'll do that at the end of March and we'll carry on doing that. But if you look at the numbers we reported yesterday, versus the underlying Medicover delta, the margins are accretive. So we're pleased. I think John says a little bit of a slower start on Synlab SEE versus City Fit. But actually both businesses are doing well. Both businesses have been revenue accretive and margin accretive to our businesses. So we're pleased with how it's going.

Matthias Waldstein
101:35 - 102:04

Well that's good. Any question in the room right now? See no hands at the moment. And maybe switching gears to genetics. You gave an update of course in the presentation, but could you give us a feel for how fast it is growing for Medicover and what makes you excited about that business for the coming years?

John Stubbington
102:04 - 104:42

A few things there. Genetics actually in 2024 did well, but they had quite a challenging year with some of their international customers who faced challenges. A good example was the NHS. The NHS we've got some agreements with, and they were going through quite a bit of change, and as a consequence, some bits slowed down. But the footprint that we've got is very, very good. I think that this is one of these longer term things for us. In my change of role, one of the things I've definitely identified is that I think our genetics business is something that could add more value. I'm not saying it doesn't add value today. More value, both for our healthcare division and for our international aspirations. So they had a good year. And they're growing quite nicely. But it's the long term, and I've alluded to it a bit for our three-year period, but we have to have some things for which I know I can pull that lever and achieve results within three years. And we also have to have some things, which is I can pull that lever, but if I get it in three years, I'll be very, very happy. John Stubbington. Being very happy is an unusual word. But if I get it in the 6 to 9, I'll be even happier. This is a really interesting area for us because we're in healthcare. And if you look at genetics, people will be saying for a long period of time, genetics is going to change the face of healthcare. Somebody's got to crack how they deliver that. Somebody's got to crack how the system works. So this is a short and long term. This is a medium to long term play for us. And the great thing about us as an organization is we've got this capability in the business. We've got these experts that are in this space, with a decent business today and a decent European business. When you look at European genetics, where the big growth is coming from, from a genetics perspective, is in America. Yeah. And of course, to do that, you've got to be one of the preferred providers embedded into the system. Yeah. So there's lots of interesting things with genetics. So it's definitely part of our strategic thinking. There's some short term. There's some medium term. There's definitely some long term in this.

Matthias Waldstein
104:43 - 104:48

But it's fair to assume that it will grow faster than the 11%.

John Stubbington
104:48 - 104:51

The team will do well. I think the team will do well.

Matthias Waldstein
104:52 - 104:56

Good. And how many countries, by the way, are you collecting revenues within genetics?

John Stubbington
104:56 - 105:00

I don't know, off the top of my head, so I couldn't answer that. I'm sorry. Yeah. Yeah.

Matthias Waldstein
105:01 - 105:20

Good. I think I'll continue with a few more questions from the audience here online. So your strategy clearly assumes EBITDA margin expansion. In which sector do you see more opportunities for this margin expansion? Is it healthcare or diagnostic?

John Stubbington
105:21 - 106:37

I think both. We've got two really good divisions. We've got some really strong positions which are growing well, which are driving the cash, which are driving the margin increase that you've seen over recent times. But also within our mix, we've got some things that we need to drive faster. We've got some things that can grow faster. Anand alluded to in his presentation, we have part of our support service area where we can integrate it much more than we have in history. That doesn't sound big, but of course that creates efficiency. And that means that as you layer on more volume through that efficiency, it starts to count. So, we've got quite a number of levers that we can pull to be able to make the mid-term targets start to move. And what we are concentrating on at the moment relates to my taking over in May. It takes a period of time to get everybody organized, everybody focused, everybody on message. We're quite happy with the development that we've done, but we think we can do a better job of engaging the leadership team to deliver more for us. And I think they will.

Unknown 5
106:37 - 107:17

I think so. Just to add to that as well. I think John's slides were excellent in showing things by country and the opportunities we have, either through non-CapEx spend by maximizing utilization or through other forms of expenditure. So I think if you replay some of those slides, we should grow EBITDA in all of those countries based on what we've said. Now clearly, there will be some material step-ups in some countries versus others, but they will be a small part of the business. So India is a good example. We should see a step up in EBITDA in India. But it's only 10% of our revenues, right. So it won't shift the dial for the whole business materially, but there's enough in there for us to believe that there's growth everywhere.

Matthias Waldstein
107:18 - 107:54

Yeah. Maybe I can follow up with a follow-up question there. Looking at the adjusted EBIT EBITDAaL margin, it's just short of 11% now, pre-pandemic. Then I'm talking 2014 to 19. It was 9.6%. So, for the broad audience, is that increase compared to this period due to better capacity utilization, or is that mainly a movement in the mix, where you are operating in more margin-accretive segments, or is it just to understand its drivers?

John Stubbington
107:54 - 108:41

Going to be both. It's going to be both. It's going to be the answer that you don't want, which is, which is both, which is good. And I think both of those levers still can be pulled. Yeah. So I don't think that we sit here today saying we've got a perfect model. We've got a really good model. We're obviously very confident. We're putting out there some ambitious targets in the Medicover way, which is, will they get them. It's ambitious. What's it going to look like. And of course, we're going to have to grow to them. But we feel we've got enough levers, and a couple that you've talked about. There are things that we can improve. So we're a really, really good business. But we've also got areas we can do better.

Matthias Waldstein
108:45 - 109:06

Good. I'll just go ahead with some other questions from the chat. And. This one relates to the number of new members that you touched upon briefly yesterday. But the question is, what is behind the sort of slowdown there? And how are you addressing that?

John Stubbington
109:06 - 110:58

If you look at our membership growth in history, part of it came from Hungary. Hungary was doing well. Hungary is not there anymore. If you look at Romania, we're remodeling Romania more to be towards the hospital clinic integrated model, less dependent on membership. So it's a smaller part of what we do. So most of our members that we talk about are in Poland. And if we look at Poland, a couple of years ago, we experienced really severe inflation that took off on day one, and we couldn't implement our price increase until about day 270. Consequently, there was a long period before we could start to reflect that extra cost in our business model. So we had a decision to make as a leadership team: what do we do? Do we price appropriately or do we use this opportunity to chase more market share, pick up membership? What matters to us now, if you look at our business mix, especially in Poland, is relationships as much as membership. Membership is one type of relationship that we have. It's an important type, but over the last two-year period, we haven't really chased volume of membership. We've chased making sure we've got the right, right price point to deliver the right care at the right time, in the right place, to the right person, for the right outcome to make the customer happy. And sometimes that's meant some of our customers have walked away because some of these price increases were really, really big. And those customers that wanted what we stand for have stayed with us. We're now going to enter a slightly different cycle. Yeah. And we should start to see relationships and members develop a little bit more in Poland because it's just a different cycle.

Matthias Waldstein
110:59 - 111:04

And maybe on that, with the price component going forward, what's the outlook there, really?

John Stubbington
111:05 - 112:18

It would still be healthy. What we had was super inflation. You know, it was really sharp. It was really quite scary at the time it happened. It's one of those Medicover moments, which I always describe as fact or fear, where the fear hits you and everybody panics. But let's deal with facts. Let's move forward and just deal with it. And then later on, we'll see how much the fear equals the fact. And it's always it's always lower. But as you look forward, medical inflation is not something that goes to zero. There's always medical inflation in the system. Doctors, nurses, people that are delivering care, scarce resources. People want them. That drives a certain wage increase that comes with it. Governments have been playing around with it now as well, forcing forcing things on us. So we'll have a decent price position. And of course, where we have the opportunity, where we have pockets where we feel we can take a slightly different value pricing position. We'll do it. So it's not going to be as rich as it has been in the last couple of years. But price will still be a component of what we talk about. It'll be an interesting couple of years. Yeah.

Matthias Waldstein
112:19 - 112:27

Yeah. And for those of you in the audience that wonder about Germany in that respect, because I assume everything you said now is basically Germany.

John Stubbington
112:27 - 113:17

From Germany, it's slightly different. It's highly regulated, so price isn't really a factor. If the fund is paying, then outside of that, there are some things which are not fund related. Therefore, if your price is regulated, we need to be extremely efficient. And part of the German reform has made us question a lot of things to do with how could we become more efficient? We obviously took actions because that's why we've come out of the reform okay. But we can do more. And as I alluded to earlier, our change process will last longer than the actual reform. And that should help manage some of our price mix positions. So again, I'm looking forward to seeing what they do.

Unknown 5
113:17 - 113:41

Yeah. So just touch a little bit more on Germany. So you're right. And I think although price is down in the public sector, what we have seen and will push for clearly is a move for fee-for-service wherever possible. But we are growing volumes as well. And the mix of tests into higher-value tests clearly generates more revenues and EBITDAs for us. We're seeing pleasing early signs from the team.

John Stubbington
113:41 - 115:22

You saw on one of my slides that I talked about lifestyle testing, which was featured there, and there's quite significant growth happening in this area. There is a trend, not just in Germany but across Europe, where you hear much more about longevity. You hear people wanting to do anti-aging, all this type of thing. We're quite well placed with our test portfolios for this kind of space, and that doesn't have a price regulation to it. In Germany and outside of Germany, it's another opportunity. So, I think one of the really big positives about Medicover is you're asking me questions about different challenges that are coming along. And they are absolutely there. And they are, they are a challenge when you're in a leadership position, you know, this is going to happen. What's it going to do to you? But then, as a Medicover leader with the capabilities we've got, if you take a step back and go, okay, that opportunity is now a little bit harder to get at. But I've still got that one and I've still got that one and I've still got that one. Yeah. So our leaders have really good opportunities to grow their businesses. And they've got a track record of going problem, solution, solution. Sometimes we need to help them to move into that process. But they've done it, and all credit to them, and you can't say a better example, and we haven't mentioned them today, and I'd like to mention Ukraine, because that team had such a big challenge from what was happening to them. And their performance in 25 has just been amazing. So all credit to them.

Matthias Waldstein
115:22 - 115:31

Good. I can see now we have a question in the back. Just make sure you have a microphone.

Unknown 7
115:32 - 115:49

Hi John. Thank you for a great presentation. I was wondering if you talked about the growth potential, but when you lose clients, what is the main reason why clients walk away from you and choose to go to a competitor?

John Stubbington
115:50 - 116:53

In recent history, it depends on the market, as we operate across various service lines. But if we go to the core Polish market. Yeah. Because Poland's our biggest country. Most of the time it's a price component. There are some companies in the market where all that matters to them is price. Yeah. And there are some of our customers that at times find themselves in a position where they have to save money and they just need to find a way to save money. And that hits us. Sometimes there's a bit of capability catch-up because we might be developing something really great, but then a competitor might introduce something similar, which requires us to respond. Oh, we've got a gap to bridge. And some people feel, 'Okay, let's have a look at that.' But then we play capability catch up, which is we build it into our into our stack and we try and move it forward. But PRICE becomes important to some customers at some time.

Unknown 7
116:54 - 116:55

So it's not product range.

John Stubbington
116:55 - 117:41

And if we look at our business-to-business sector, we tailor our products. Our products are built from scratch. So the customer says what they want. And we design what they want. And if we look at our portfolio of different product solutions that we have, we've got the broadest portfolio of product solutions. Certainly in Poland, across different businesses and areas of focus that we have. So no, but you know, if you're going to tell me something in the end that I should know about, I'm quite happy to listen. Yeah. I don't want to sit here and say, we've got all the answers because we haven't and we're quite prepared to be challenged. Listen, learn and solve.

Unknown 7
117:42 - 117:43

Helpful. So no, but if you're going to tell me something in the end that I should know about, I'm quite happy to listen.

John Stubbington
117:43 - 117:44

No problem.

Matthias Waldstein
117:46 - 117:52

Any more questions in the room right now? One question in the front here.

Unknown 4
117:55 - 118:11

A follow-up question on Ukraine: I understand that it's difficult to assess, but what would a peace scenario mean? Is that an instant ramp-up of sales or a lifting of the margin, or what would you say on that?

John Stubbington
118:12 - 120:02

I think it'd be very difficult to say what would happen. I think if the war ended in Ukraine tomorrow, there would probably be some population shifts. So some population from Poland going back, some population from Ukraine that couldn't get out would want to get out. So there'd be a change in the market dynamics. But also then there would be a massive building program that starts to happen in the country. One of the challenges that might happen for us is actually the cost of building and resources for people to build, because it will be sucked into Ukraine. And that's one of the scenarios that we need to think about. But there'll definitely be an opportunity for a player like us, as we are very respected in the country. Everybody knows that if they come to us because consumers come to us mainly directly to have their tests done, and they know if they come to us, the test is done. And there's an opportunity for us to move deeper into healthcare in that particular country given the scale of its population. So, as I've answered before, we have a business-as-usual approach, and our team is doing fantastically; all credit to them. And then, at a relatively detailed level, we've got the things we would consider if war ended. But we're not going to say let's press the button because there's going to be an environment shift that happens. And we need to assess what that environment shift looks like. So quite a difficult question to answer. But if you take a complete step back, think about it logically and let everything settle. We're a significant player in Ukraine that's trusted. That surely puts us in a better place than most people who would want to explore Ukraine.

Unknown 4
120:03 - 120:10

But we're not going to say, 'Let's press the button,' because there's going to be an environment shift that happens. And a short follow up there. Should we assume that the margin there is below?

John Stubbington
120:10 - 120:13

You should never assume anything in life. No.

Unknown 4
120:14 - 120:20

Or perhaps it is not at the same level as it was around 2019 and during Covid.

John Stubbington
120:20 - 120:44

We do not give out margins by individual business lines. So I want to answer your question as a human being, but we just don't do it. But, I'll go back to what I have said, which is that business has done incredibly well in 2025. Yeah. And you should read into that what you'd like to read into it.

Unknown 4
120:44 - 120:45

But we're not going to say let's press the button because there's going to be an environment shift that happens. But if you take a complete step back, think about it logically and let everything settle.

Matthias Waldstein
120:46 - 121:01

Good. A couple more online here. Are important regulatory changes anticipated in the next 1 to 2 years that could create opportunities or challenges?

John Stubbington
121:01 - 122:04

There are always regulatory changes being talked about, so when we map those out and have sessions with our people who are responsible for looking at it, they love to gossip and they love to scare you. And there are so many of them, you look at them and go, 'Well, which one should we focus on?' And we have a process for what we think is real. And what we think isn't so real. And you know what? There's nothing in it at the moment where we're going. Oh my God, oh my God. But you never know what's going to change. And I'll answer it the same way that I have a little bit earlier, which is there are two choices. You can either go with fact or fear. We'll go with fact. So we have a track record that shows no matter what change has occurred, we've been agile enough, both as a leadership community and mentally, to quickly adapt and develop our business going forward. And it's one of those scenarios where, when one door closes, another opens.

Matthias Waldstein
122:06 - 122:29

Good. I think we are running short of time. I hear you there. So I'm sure that those questions that were not asked online, they can be addressed to Medicover afterwards. And you will get the answers. And as we approach the end of the event here, I think I'll hand it over to you, John, for some closing remarks.

John Stubbington
122:29 - 123:42

Sure, sure. And as we approach the end of the event here, I think I'll hand it over to you, John, for some closing remarks. So I'm not going to take too much time for everybody because we've spent a lot of time in the room. We've covered a lot of ground. I think you've heard quite a lot of exciting things from us. What are the key takeaway messages? First and foremost, Medicover is in a really good place. We've got really good capability. We've got really good teams. We've got passionate teams that really want to do a good job for the customer. We've got a track record of delivery. We've got some exciting plans underway, and we've set ambitious targets. They're ambitious. They're challenging, but they're the type of things that we like to do. And we're looking forward to developing them and our business over the next three years. There's lots of levers that we can pull for growth. There are lots of levers that we can pull to improve our operating position. And we're looking forward to sharing the journey with you in the coming quarters and the coming years. Thank you very much for your attendance. Thank you very much for your support. And, and thank you. This is the end. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…